why choose us

First received: November 30, 2022

Clinical Trial: Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)

Study Status: Completed

Recruit Status: RECRUITING

Condition: Recurrent Lung Non-Small Cell Carcinoma

Study Type: INTERVENTIONAL


Official Title: A Randomized Phase II Study of INC280 (Capmatinib) Plus Osimertinib With or Without Ramucirumab in Participants With EGFR-Mutant, MET-Amplified Stage IV or Recurrent Non-Small Cell Lung Cancer (Lung-M

Brief Summary: This phase II Lung-MAP treatment trial test the combination of targeted drugs (capmatinib, osimertinib, and/or ramucirumab) in treating patients with non-small cell lung cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) and that has EGFR and MET gene changes.Capmatinib and osimertinib are in a class of medications called kinase inhibitors.They work by blocking the action of the abnormal protein that signals cancer cells to…

Read more